BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16306851)

  • 1. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
    de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
    Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
    Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
    Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
    Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH
    J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):211-30. PubMed ID: 11468938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
    de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):135-56. PubMed ID: 15379382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
    de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
    Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
    Huitema AD; Kerbusch T; Tibben MM; Rodenhuis S; Beijnen JH
    Cancer Chemother Pharmacol; 2000; 46(2):119-27. PubMed ID: 10972481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
    Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
    Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
    Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
    De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
    de Jonge ME; van Dam SM; Hillebrand MJ; Rosing H; Huitema AD; Rodenhuis S; Beijnen JH
    J Mass Spectrom; 2004 Mar; 39(3):262-71. PubMed ID: 15039933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
    de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
    Ther Drug Monit; 2005 Jun; 27(3):393-402. PubMed ID: 15905813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.
    Huang L; Winger BA; Cheah V; Gingrich D; Marzan F; Lu Y; Cooper JC; Aweeka F; Long-Boyle J
    J Chromatogr Open; 2022 Nov; 2():. PubMed ID: 35875822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
    Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
    Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
    de Jonge ME; Mathôt RA; Dalesio O; Huitema AD; Rodenhuis S; Beijnen JH
    Bone Marrow Transplant; 2002 Nov; 30(9):593-7. PubMed ID: 12407434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
    Ekhart C; Kerst JM; Rodenhuis S; Beijnen JH; Huitema AD
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):375-9. PubMed ID: 18431571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
    de Jonge ME; Huitema AD; Beijnen JH; Rodenhuis S
    Br J Cancer; 2006 May; 94(9):1226-30. PubMed ID: 16622453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
    van Maanen MJ; Huitema AD; Rodenhuis S; Beijnen JH
    Anticancer Drugs; 2001 Jul; 12(6):519-24. PubMed ID: 11459998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
    Hassan M; Svensson US; Ljungman P; Björkstrand B; Olsson H; Bielenstein M; Abdel-Rehim M; Nilsson C; Johansson M; Karlsson MO
    Br J Clin Pharmacol; 1999 Nov; 48(5):669-77. PubMed ID: 10594468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.